Revolutionary biologicals: painless in rheumatic diseases!

Revolutionary biologicals: painless in rheumatic diseases!

AT, Österreich - Modern medicine has made a decisive progress in therapy in inflammatory diseases with the development of biologicals. These highly effective substances, also known as biological medicines, revolutionized the treatment of diseases such as rheumatoid arthritis and psoriasis. Biologics are blocking inflammatory messenger substances of the immune system and thus contributed to significantly reducing inflammation and joint artery disorders. Affected patients often experience remarkable freedom of pain after a short time, which significantly increases the quality of life. krone.at/3737448"> Krone reports that the treating rheumatologist selects the most suitable preparation from a variety of options.

The administration of these drugs is either an infusion or subcutaneous, i.e. by spraying under the skin, since oral intake is not possible. This method enables a faster effect compared to classic basic medication, with a reduction in the disease activity, which uses after two to four weeks.

therapy options and conditions

The switch to biologicals usually takes place when conventional synthetic basic therapy agents (CSDMARD) do not show the desired effect within three months. This applies particularly to patients with a serious course of illness and high activity of the disease. In such cases, a biological can also be used as monotherapy, for example if the patient does not appeal to methotrexate or other CSDMARD or does not tolerate it. Therapy rheumatism emphasizes that the prescription of biologicals should be carried out by specialized rheumatologists in order to adequately weep.

The choice of biological also depends on the specific mechanism of action. In the case of insufficient effectiveness, a different biological can be switched to better respond to the patient's needs. rheuma-league informs that the side effects and contraindications of biologicals cannot be ignored. In particular, before the start of the therapy, doctors must ensure that there are no infectious diseases and that the patient's vaccination status should be checked, since patients under biologics may not be vaccinated with living vaccines.

List of biologicals approved in the EU

Currently there are numerous biologicals in the EU that aim at various rheumatological diseases. Here is an overview of the common therapeutics: